In 2007, agents known as incretins became available for the treatment of type 2 diabetes in the UK. Sitagliptin, an oral DPP-4 inhibitor, and exenatide, an injectable GLP-1 agonist have become widely used in clinical practice and have been followed on to the market by another three incretin agents. The area continues to develop with the anticipated launch of once-weekly GLP-1 agonist later this year and reports of the efficacy of once-a-month regimens.

Read More ››